Across 31 trials in 9,437 middle-aged and older men, testosterone replacement therapy lowered total cholesterol, triglycerides and LDL cholesterol and improved measures of artery health, but arrhythmias were more common in men on treatment.
What it shows: Solid on the risk markers, unresolved on heart rhythm: results pooled from 31 trials in 9,437 middle-aged and older men with low or low-normal testosterone, lasting from 40 days to 36 months. The extra arrhythmias showed up clearly in the data, but their real-world clinical importance remains uncertain.Meta-analysis · Endocrine